Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Arcturus Therapeutics Holdings (ARCT) Leases (2019 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Leases for 7 consecutive years, with $21.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Leases fell 20.97% year-over-year to $21.1 million, compared with a TTM value of $21.1 million through Dec 2025, down 20.97%, and an annual FY2025 reading of $21.1 million, down 20.97% over the prior year.
  • Leases was $21.1 million for Q4 2025 at Arcturus Therapeutics Holdings, down from $23.8 million in the prior quarter.
  • Across five years, Leases topped out at $34.5 million in Q2 2022 and bottomed at $5.2 million in Q1 2022.
  • Average Leases over 5 years is $22.9 million, with a median of $27.1 million recorded in 2024.
  • The sharpest move saw Leases fell 21.6% in 2022, then soared 501.66% in 2023.
  • Year by year, Leases stood at $5.6 million in 2021, then soared by 479.3% to $32.5 million in 2022, then fell by 12.43% to $28.5 million in 2023, then dropped by 6.41% to $26.7 million in 2024, then decreased by 20.97% to $21.1 million in 2025.
  • Business Quant data shows Leases for ARCT at $21.1 million in Q4 2025, $23.8 million in Q3 2025, and $24.8 million in Q2 2025.